Relmada Therapeutics (RLMD) Common Equity (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Common Equity data on file, last reported at $218.7 million in Q1 2026.

• Common Equity for Q1 2026 came in at $218.7 million, up 874.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $218.7 million (up 874.72% YoY), and the FY2025 annual result was $86.5 million, up 143.55% from the prior year.
• Common Equity rose to $218.7 million in Q1 2026 per RLMD's latest filing, from $86.5 million in the prior quarter.
• Over five years, Common Equity peaked at $218.7 million in Q1 2026 and troughed at $9.5 million in Q3 2025.
• A 5-year average of $100.4 million and a median of $86.5 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2025 and 2026: Common Equity tumbled 80.12% in 2025, then soared 874.72% in 2026.
• A 5-year view of Common Equity shows it stood at $140.4 million in 2022, then tumbled by 39.22% to $85.4 million in 2023, then tumbled by 58.38% to $35.5 million in 2024, then jumped by 143.55% to $86.5 million in 2025, then soared by 152.83% to $218.7 million in 2026.
• Business Quant data shows RLMD's Common Equity at $218.7 million in Q1 2026, $86.5 million in Q4 2025, and $9.5 million in Q3 2025.